WhartSep
Severe Pneumonia (leading to septic shock/ARDS)
Phase 1Active
Key Facts
About StemInov
StemInov is advancing a novel cell therapy platform based on Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) for severe inflammatory conditions, with an initial focus on septic shock and ARDS stemming from severe pneumonia. Its lead product, WhartSep, is designed as a scalable, off-the-shelf therapy with three complementary mechanisms of action: antibacterial effects, immunomodulation, and organ protection. The company is preparing for a Phase Ib/IIa clinical trial in ICU patients, leveraging strong preclinical data and a founding team with deep clinical and scientific expertise in intensive care and cell therapy.
View full company profile